Hepatoprotective effects of chinese medicinal herbs: A focus on anti-inflammatory and anti-oxidative activities

International Journal of Molecular Sciences

Volumn 17, Issue 4, 2016, Pages

  Lam, Puiyan ^a   Cheung, Fan ^a   Tan, Hor Yue ^a   Wang, Ning ^a   Yuen, Man Fung ^b   Feng, Yibin ^a  

^a THE UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti inflammatory; Anti oxidative; Chinese medicinal herbs; Hepatoprotection; Liver diseases

Indexed keywords

ANDROGRAPHIS HERBA EXTRACT; CARNITINE PALMITOYLTRANSFERASE I; CHINESE DRUG; COPTIS RHIZOME EXTRACT; CURCUMIN; GINSENG EXTRACT; GLYCYRRHIZA EXTRACT; LYCII FRUCTUS EXTRACT; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; HERBACEOUS AGENT; PROTECTIVE AGENT;

ALCOHOL LIVER DISEASE; ANDROGRAPHIS HERBA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CHINESE MEDICINE; COPTIS; DNA METHYLATION; FATTY ACID OXIDATION; GINSENG; GLYCYRRHIZA; HEPATITIS B; HEPATITIS C; HUMAN; INFLAMMATION; KUPFFER CELL; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; LIVER PROTECTION; MEDICINAL PLANT; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; REVIEW; STELLATE CELL; TOXIC HEPATITIS; WOUND HEALING; CHEMISTRY; DRUG EFFECTS; LIVER DISEASES; PHYTOTHERAPY;

ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; DNA METHYLATION; DRUGS, CHINESE HERBAL; HUMANS; INFLAMMATION; LIVER DISEASES; MEDICINE, CHINESE TRADITIONAL; OXIDATIVE STRESS; PHYTOTHERAPY; PROTECTIVE AGENTS;

EID: 84962069064     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17040465     Document Type: Review

References (351)

1. Wood, N.J. Liver: Nonobese individuals in the developing world are at risk of nonalcoholic fatty liver and liver disease. Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 357-357
2. Fattovich, G.; Stroffolini, T.; Zagni, I.; Donato, F. Hepatocellular carcinoma in cirrhosis: Incidence and risk factors. Gastroenterology 2004, 127, S35-S50
3. Bonacchi, A.; Petrai, I.; Defranco, R.M.; Lazzeri, E.; Annunziato, F.; Efsen, E.; Cosmi, L.; Romagnani, P.; Milani, S.; Failli, P. The chemokine CCL21 modulates lymphocyte recruitment and fibrosis in chronic hepatitis C. Gastroenterology 2003, 125, 1060-1076
4. Seki, E.; de Minicis, S.; Österreicher, C.H.; Kluwe, J.; Osawa, Y.; Brenner, D.A.; Schwabe, R.F. TLR4 enhances TGF-β signaling and hepatic fibrosis. Nat. Med. 2007, 13, 1324-1332
5. Guo, J.; Loke, J.; Zheng, F.; Hong, F.; Yea, S.; Fukata, M.; Tarocchi, M.; Abar, O.T.; Huang, H.; Sninsky, J.J. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009, 49, 960-968
6. Seki, E.; de Minicis, S.; Gwak, G.-Y.; Kluwe, J.; Inokuchi, S.; Bursill, C.A.; Llovet, J.M.; Brenner, D.A.; Schwabe, R.F. CCR1 and CCR5 promote hepatic fibrosis in mice. J. Clin. Investig. 2009, 119, 1858-1870
7. Dominguez, M.; Miquel, R.; Colmenero, J.; Moreno, M.; García-Pagán, J.C.; Bosch, J.; Arroyo, V.; Ginès, P.; Caballería, J.; Bataller, R. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology 2009, 136, 1639-1650
8. Miura, K.; Kodama, Y.; Inokuchi, S.; Schnabl, B.; Aoyama, T.; Ohnishi, H.; Olefsky, J.M.; Brenner, D.A.; Seki, E. Toll-like receptor 9 promotes steatohepatitis by induction of interleukin-1β in mice. Gastroenterology 2010, 139, 323-334
9. Karin, M.; Ben-Neriah, Y. Phosphorylation meets ubiquitination: The control of NF-κB activity. Annu. Rev. Immunol. 2000, 18, 621-663
10. Ghosh, S.; Karin, M. Missing pieces in the NF-κB puzzle. Cell 2010, 109, S81-S96
11. Xiao, C.; Ghosh, S. NF-κB, an evolutionarily conserved mediator of immune and inflammatory responses. In Mechanisms of Lymphocyte Activation and Immune Regulation x; Springer: Berlin, Germany, 2005; pp. 41-45.
12. Bartsch, H.; Nair, J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: Role of lipid peroxidation, DNA damage, and repair. Langenbeck's Arch. Surg. 2006, 391, 499-510
13. Visconti, R.; Grieco, D. New insights on oxidative stress in cancer. Curr. Opin. Drug Discov. Dev. 2009, 12, 240-245.
14. Invernizzi, P. Liver auto-immunology: The paradox of autoimmunity in a tolerogenic organ. J. Autoimmun. 2013, 46, 1-6
15. Elsharkawy, A.M.; Mann, D.A. Nuclear factor-κB and the hepatic inflammation-fibrosis-cancer axis. Hepatology 2007, 46, 590-597
16. Wang, B.E. Treatment of chronic liver diseases with traditional chinese medicine. J. Gastroenterol. Hepatol. 2000, 15, E67-E70
17. Dhiman, A.; Nanda, A.; Ahmad, S. A recent update in research on the antihepatotoxic potential of medicinal plants. Zhong Xi Yi Jie He Xue Bao = J. Chin. Integr. Med. 2012, 10, 117-127
18. Del Prete, A.; Scalera, A.; Iadevaia, M.D.; Miranda, A.; Zulli, C.; Gaeta, L.; Tuccillo, C.; Federico, A.; Loguercio, C. Herbal products: Benefits, limits, and applications in chronic liver disease. Evid. Based Complement. Altern. Med. 2012, 2012
19. Wang, X.; Wang, N.; Cheung, F.; Lao, L.; Li, C.; Feng, Y. Chinese medicines for prevention and treatment of human hepatocellular carcinoma: Current progress on pharmacological actions and mechanisms. J. Integr. Med. 2015, 13, 142-164
20. Rolo, A.P.; Teodoro, J.S.; Palmeira, C.M. Role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis. Free Radic. Biol. Med. 2012, 52, 59-69
21. Hu, Y.; Wang, S.; Wu, X.; Zhang, J.; Chen, R.; Chen, M.; Wang, Y. Chinese herbal medicine-derived compounds for cancer therapy: A focus on hepatocellular carcinoma. J. Ethnopharmacol. 2013, 149, 601-612
22. Chatterjee, R.; Mitra, A. An overview of effective therapies and recent advances in biomarkers for chronic liver diseases and associated liver cancer. Int. Immunopharmacol. 2015, 24, 335-345
23. Mehal, W.Z. The gordian knot of dysbiosis, obesity and nafld. Nat. Rev. Gastroenterol. Hepatol. 2013, 10, 637-644
24. Chen, P.J.; Huang, C.; Meng, X.M.; Li, J. Epigenetic modifications by histone deacetylases: Biological implications and therapeutic potential in liver fibrosis. Biochimie 2015, 116, 61-69
25. Duval, F.; Moreno-Cuevas, J.E.; Gonzalez-Garza, M.T.; Rodriguez-Montalvo, C.; Cruz-Vega, D.E. Protective mechanisms of medicinal plants targeting hepatic stellate cell activation and extracellular matrix deposition in liver fibrosis. Chin. Med. 2014, 9
26. Diesen, D.L.; Kuo, P.C. Nitric oxide and redox regulation in the liver: Part II. Redox biology in pathologic hepatocytes and implications for intervention. J. Surg. Res. 2011, 167, 96-112
27. Santos, J.C.; Valentim, I.B.; de Araujo, O.R.; Ataide Tda, R.; Goulart, M.O. Development of nonalcoholic hepatopathy: Contributions of oxidative stress and advanced glycation end products. Int. J. Mol. Sci. 2013, 14, 19846-19866
28. Leung, C.C.H.; Young, K.K. Clinical aspects of hepatic disease. Anaesth. Intensive Care Med. 2015, 16, 11-13
29. Chen, Y.; Dong, H.; Thompson, D.C.; Shertzer, H.G.; Nebert, D.W.; Vasiliou, V. Glutathione defense mechanism in liver injury: Insights from animal models. Food Chem. Toxicol. 2013, 60, 38-44
30. Edwards, L.; Wanless, I.R. Mechanisms of liver involvement in systemic disease. Best Pract. Res. Clin. Gastroenterol. 2013, 27, 471-483
31. - in mediating the toxicity of O*. Free Radic. Biol. Med. 1999, 26, 777-778
32. Center, S.A. Metabolic, antioxidant, nutraceutical, probiotic, and herbal therapies relating to the management of hepatobiliary disorders. Vet. Clin. N. Am. Small Anim. Pract. 2004, 34, 67-172
33. Raschzok, N.; Sallmon, H.; Pratschke, J.; Sauer, I.M. Micrornas in liver tissue engineering-New promises for failing organs. Adv. Drug Deliv. Rev. 2015, 88, 67-77
34. Moore, S.M.; Kremer, M.; Sanderlin, E.J., 3rd; Wheeler, M.D.; Hines, I.N. Emerging roles for lipids in the hepatic innate immune response. J. Hum. Nutr. Food Sci. 2013, 1, 1009.
35. Videla, L.A.; Rodrigo, R.; Orellana, M.; Fernandez, V.; Tapia, G.; Quinones, L.; Varela, N.; Contreras, J.; Lazarte, R.; Csendes, A. Oxidative stress-related parameters in the liver of non-alcoholic fatty liver disease patients. Clin. Sci. 2004, 106, 261-268
36. Benoît, D.A.; Michel, B.T. ROS as signalling molecules: Mechanisms that generate specificity in ROS homeostasis. Nat. Rev. Mol. Cell Biol. 2007, 8, 813-824.
37. Mittler, R.; Vanderauwera, S.; Suzuki, N.; Miller, G.; Tognetti, V.B.; Vandepoele, K.; Gollery, M.; Shulaev, V.; van Breusegem, F. ROS signaling: The new wave? Trends Plant Sci. 2011, 16, 300-309
38. Tell, G.; Vascotto, C.; Tiribelli, C. Alterations in the redox state and liver damage: Hints from the easl basic school of hepatology. J. Hepatol. 2013, 58, 365-374
39. Bhogal, R.H.; Curbishley, S.M.; Weston, C.J.; Adams, D.H.; Afford, S.C. Reactive oxygen species mediate human hepatocyte injury during hypoxia/reoxygenation. Liver Transplant. 2010, 16, 1303-1313
40. Miura, K.; Taura, K.; Kodama, Y.; Schnabl, B.; Brenner, D.A. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Hepatology 2008, 48, 1420-1429
41. Takaki, A.; Yamamoto, K. Control of oxidative stress in hepatocellular carcinoma: Helpful or harmful? World J. Hepatol. 2015, 7, 968-979
42. Valavanidis, A.; Vlachogianni, T.; Fiotakis, C. 8-hydroxy-21-deoxyguanosine (8-OHdG): A critical biomarker of oxidative stress and carcinogenesis. J. Environ. Sci. Health Part C 2009, 27, 120-139
43. Marí, M.; Colell, A.; Morales, A.; von Montfort, C.; Garcia-Ruiz, C.; Fernández-Checa, J.C. Redox control of liver function in health and disease. Antioxid. Redox Signal. 2010, 12, 1295-1331
44. Serviddio, G.; Bellanti, F.; Vendemiale, G. Free radical biology for medicine: Learning from nonalcoholic fatty liver disease. Free Radic. Biol. Med. 2013, 65, 952-968
45. Vasconcelos, S.M.L.; Goulart, M.O.F.; Moura, J. d. F.; Manfredini, V.; Benfato, M.d.S.; Kubota, L.T. Espécies reativas de oxigênio e de nitrogênio, antioxidantes e marcadores de dano oxidativo em sangue humano: Principais métodos analíticos para sua determinação. Quim. Nova 2007, 30, 1323-1338
46. Zhou, W.-C.; Zhang, Q.-B.; Qiao, L. Pathogenesis of liver cirrhosis. World J. Gastroenterol. WJG 2014, 20, 7312-7324
47. Baffy, G. Kupffer cells in non-alcoholic fatty liver disease: The emerging view. J. Hepatol. 2009, 51, 212-223
48. Da Costa Silva, D.; Cerchiaro, G.; Honório, K.M. Relações patofisiológicas entre estresse oxidativo E arteriosclerose. Quim. Nova 2011, 34, 300-305
49. Czaja, A.J. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J. Gastroenterol. 2014, 20, 2515-2532
50. Compare, D.; Coccoli, P.; Rocco, A.; Nardone, O.; de Maria, S.; Cartenì, M.; Nardone, G. Gut-liver axis: The impact of gut microbiota on non alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 2012, 22, 471-476
51. Reuter, S.; Gupta, S.C.; Chaturvedi, M.M.; Aggarwal, B.B. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic. Biol. Med. 2010, 49, 1603-1616
52. Mormone, E.; George, J.; Nieto, N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem. Biol. Interact. 2011, 193, 225-231
53. Haddad, J.J. Oxygen homeostasis, thiol equilibrium and redox regulation of signalling transcription factors in the alveolar epithelium. Cell Signal. 2002, 14, 799-810
54. Giraudi, P.J.; Becerra, V.J.B.; Marin, V.; Chavez-Tapia, N.C.; Tiribelli, C.; Rosso, N. The importance of the interaction between hepatocyte and hepatic stellate cells in fibrogenesis induced by fatty accumulation. Exp. Mol. Pathol. 2015, 98, 85-92
55. Nakamoto, N.; Kanai, T. Role of toll-like receptors in immune activation and tolerance in the liver. Front. Immunol. 2014, 5
56. Pelz, S.; Stock, P.; Brückner, S.; Christ, B. A methionine-choline-deficient diet elicits NASH in the immunodeficient mouse featuring a model for hepatic cell transplantation. Exp. Cell Res. 2012, 318, 276-287
57. Hayes, P.; Knaus, U.G. Balancing reactive oxygen species in the epigenome: NADPH oxidases as target and perpetrator. Antioxid. Redox Signal. 2013, 18, 1937-1945
58. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16, 6-21
59. Ehrlich, M.; Gama-Sosa, M.A.; Huang, L.H.; Midgett, R.M.; Kuo, K.C.; McCune, R.A.; Gehrke, C. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. Nucleic Acids Res. 1982, 10, 2709-2721
60. Jones, P.A.; Takai, D. The role of DNA methylation in mammalian epigenetics. Science 2001, 293, 1068-1070
61. Larsen, F.; Gundersen, G.; Lopez, R.; Prydz, H. CpG islands as gene markers in the human genome. Genomics 1992, 13, 1095-1107
62. Bestor, T.H.; Gundersen, G.; Kolstø, A.-B.; Prydz, H. CpG islands in mammalian gene promoters are inherently resistant to de novo methylation. Genet. Anal. Biomol. Eng. 1992, 9, 48-53
63. Pradhan, S.; Bacolla, A.; Wells, R.D.; Roberts, R.J. Recombinant human DNA (cytosine-5) methyltransferase. I. Expression, purification, and comparison of novo and maintenance methylation. J. Biol. Chem. 1999, 274, 33002-33010
64. En, L.; Caroline, B.; Rudolf, J. Role for DNA methylation in genomic imprinting. Nature 1993, 366, 362-365.
65. Beard, C.; Jaenisch, R.; Li, E. Loss of methylation activates xist in somatic but not in embryonic cells. Genes Dev. 1995, 9, 2325-2334
66. Afanas’Ev, I. New nucleophilic mechanisms of ROS-dependent epigenetic modifications: Comparison of aging and cancer. Aging Dis. 2014, 5, 52-62
67. Masaki, O.; Shaoping, X.; En, L. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat. Genet. 1998, 19, 219-220.
68. Okano, M.; Bell, D.W.; Haber, D.A.; Li, E. DNA methyltransferases DNMT3a and DNMT3b are essential for de novo methylation and mammalian development. Cell 1999, 99, 247-257
69. Hsieh, C.-L. In vivo activity of murine de novo methyltransferases, DNMT3a and DNMT3b. Mol. Cell. Biol. 1999, 19, 8211-8218
70. Bestor, T.H. The DNA methyltransferases of mammals. Hum. Mol. Genet. 2000, 9, 2395-2402
71. Morgan, H.D.; Santos, F.; Green, K.; Dean, W.; Reik, W. Epigenetic reprogramming in mammals. Hum. Mol. Genet. 2005, 14, R47-R58
72. Fatemi, M.; Hermann, A.; Gowher, H.; Jeltsch, A. DNMT3a and DNMT1 functionally cooperate during de novo methylation of DNA. Eur. J. Biochem. 2002, 269, 4981-4984
73. Kim, G.D.; Ni, J.; Kelesoglu, N.; Roberts, R.J.; Pradhan, S. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J. 2002, 21, 4183-4195
74. Boyes, J.; Bird, A. Repression of genes by DNA methylation depends on CPG density and promoter strength: Evidence for involvement of a methyl-CPG binding protein. EMBO J. 1992, 11, 327-333
75. Hsieh, C.L. Dependence of transcriptional repression on CPG methylation density. Mol. Cell. Biol. 1994, 14, 5487-5494
76. Kass, S.U.; Landsberger, N.; Wolffe, A.P. DNA methylation directs a time-dependent repression of transcription initiation. Curr. Biol. 1997, 7, 157-165
77. Arnaud, P.; Feil, R. Epigenetic deregulation of genomic imprinting in human disorders and following assisted reproduction. Birth Defects Res. Part C Embryo Today Rev. 2005, 75, 81-97
78. Graves, J.A. 5-Azacytidine-induced re-expression of alleles on the inactive X chromosome in a hybrid mouse cell line. Exp. Cell Res. 1982, 141, 99-105
79. Venolia, L.; Gartler, S.M.; Wassman, E.R.; Yen, P.; Mohandas, T.; Shapiro, L.J. Transformation with DNA from 5-azacytidine-reactivated X chromosomes. Proc. Natl. Acad. Sci. USA 1982, 79, 2352-2354
80. Mohandas, T.; Sparkes, R.S.; Shapiro, L.J. Reactivation of an inactive human X chromosome: Evidence for X inactivation by DNA methylation. Science 1981, 211, 393-396
81. Sado, T.; Fenner, M.H.; Tan, S.-S.; Tam, P.; Shioda, T.; Li, E. X inactivation in the mouse embryo deficient for DNMT1: Distinct effect of hypomethylation on imprinted and random X inactivation. Dev. Biol. 2000, 225, 294-303
82. Miranda, T.B.; Jones, P.A. DNA methylation: The nuts and bolts of repression. J. Cell. Physiol. 2007, 213, 384-390
83. Nanduri, J.; Makarenko, V.; Reddy, V.D.; Yuan, G.; Pawar, A.; Wang, N.; Khan, S.A.; Zhang, X.; Kinsman, B.; Peng, Y.-J.; et al. Epigenetic regulation of hypoxic sensing disrupts cardiorespiratory homeostasis. Proc. Natl. Acad. Sci. USA 2012, 109, 2515-2520
84. Campos, A.C.E.; Molognoni, F.; Melo, F.H.M.; Galdieri, L.C.; Carneiro, C.R.W.; D'Almeida, V.; Correa, M.; Jasiulionis, M.G. Oxidative stress modulates DNA methylation during melanocyte anchorage blockade associated with malignant transformation. Neoplasia 2007, 9, 1111-1121
85. Hitchler, M.J.; Domann, F.E. An epigenetic perspective on the free radical theory of development. Free Radic. Biol. Med. 2007, 43, 1023-1036
86. Wongpaiboonwattana, W.; Tosukhowong, P.; Dissayabutra, T.; Mutirangura, A.; Boonla, C. Oxidative stress induces hypomethylation of line-1 and hypermethylation of the RUNX3 promoter in a bladder cancer cell line. Asian Pac. J. Cancer Prev. 2013, 14, 3773-3778
87. Cyr, A.; Hitchler, M.; Domann, F. Regulation of SOD2 in cancer by histone modifications and CPG methylation: Closing the loop between redox biology and epigenetics. Antioxid. Redox Signal. 2013, 18, 1946-1955
88. Zhang, R.; Kang, K.A.; Kim, K.C.; Na, S.-Y.; Chang, W.Y.; Kim, G.Y.; Kim, H.S.; Hyun, J.W. Oxidative stress causes epigenetic alteration of CDX1 expression in colorectal cancer cells. Gene 2013, 524, 214-219
89. Xiong, F.; Xiao, D.; Zhang, L. Norepinephrine causes epigenetic repression of PKCε gene in rodent hearts by activating NOX1-dependent reactive oxygen species production. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol. 2012, 26, 2753-2763.
90. Hodge, D.R.; Peng, B.; Pompeia, C.; Thomas, S.; Cho, E.; Clausen, P.A.; Marquez, V.E.; Farrar, W.L. Epigenetic silencing of manganese superoxide dismutase (SOD-2) in KAS 6/1 human multiple myeloma cells increases cell proliferation. Cancer Biol. Ther. 2005, 4, 585-592
91. Kamiya, T.; Machiura, M.; Makino, J.; Hara, H.; Hozumi, I.; Adachi, T. Epigenetic regulation of extracellular-superoxide dismutase in human monocytes. Free Radic. Biol. Med. 2013, 61, 197-205
92. Zelko, I.N.; Mueller, M.R.; Folz, R.J. CpG methylation attenuates Sp1 and Sp3 binding to the human extracellular superoxide dismutase promoter and regulates its cell-specific expression. Free Radic. Biol. Med. 2010, 48, 895-904
93. Chen, B.; Rao, X.; House, M.G.; Nephew, K.P.; Cullen, K.J.; Guo, Z. GPX3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. Cancer Lett. 2011, 309, 37-45
94. Hahn, M.A.; Hahn, T.; Lee, D.-H.; Esworthy, R.S.; Kim, B.-W.; Riggs, A.D.; Chu, F.-F.; Pfeifer, G.P. Methylation of polycomb target genes in intestinal cancer is mediated by inflammation. Cancer Res. 2008, 68, 10280-10289
95. Lee, O.-J.; Schneider-Stock, R.; McChesney, P.A.; Kuester, D.; Roessner, A.; Vieth, M.; Moskaluk, C.A.; El-Rifai, W.E. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett’s tumorigenesis. Neoplasia 2005, 7, 854-861
96. Peng, D.F.; Razvi, M.; Chen, H.; Washington, K.; Roessner, A.; Schneider-Stock, R.; El-Rifai, W. DNA hypermethylation regulates the expression of members of the mu-class glutathione-transferases and glutathione peroxidases in Barrett’s adenocarcinoma. Gut 2009, 58, 5-15
97. Khor, T.O.; Huang, Y.; Wu, T.-Y.; Shu, L.; Lee, J.; Kong, A.-N.T. Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of NRF2 via promoter CPGs demethylation. Biochem. Pharmacol. 2011, 82, 1073-1078
98. Min, J.Y.; Lim, S.-O.; Jung, G. Downregulation of catalase by reactive oxygen species via hypermethylation of CPG island ii on the catalase promoter. FEBS Lett. 2010, 584, 2427-2432
99. Fang, M.; Chen, D.; Yang, C.S. Dietary polyphenols may affect DNA methylation. J. Nutr. 2007, 137, 223S-228S
100. Yang, C.S.; Fang, M.; Lambert, J.D.; Yan, P.; Huang, T.H.M. Reversal of hypermethylation and reactivation of genes by dietary polyphenolic compounds. Nutr. Rev. 2008, 66, S18-S20
101. Fang, M.Z.; Chen, D.; Sun, Y.; Jin, Z.; Yang, C.S.; Christman, J.K. Reversal of hypermethylation and reactivation of p16 INK4a, RARβ, and MGMT genes by genistein and other isoflavones from SOY. Clin. Cancer Res. 2005, 11, 7033-7041
102. Cohen-Naftaly, M.; Friedman, S.L. Current status of novel antifibrotic therapies in patients with chronic liver disease. Ther. Adv. Gastroenterol. 2011, 137, 391-417
103. Jiang, L.; Wang, L.; Chen, L.; Cai, G.-H.; Ren, Q.-Y.; Chen, J.-Z.; Shi, H.-J.; Xie, Y.-H. As2O3 induces apoptosis in human hepatocellular carcinoma HEPG2 cells through a ROS-mediated mitochondrial pathway and activation of caspases. Int. J. Clin. Exp. Med. 2015, 8, 2190-2196
104. Borro, P.; Leone, S.; Testino, G. Liver disease and hepatocellular carcinoma in alcoholics: The role of anticraving therapy. Curr. Drug Targets 2015, 17, 239-251
105. Roessner, A.; Kuester, D.; Malfertheiner, P.; Schneider-Stock, R. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol. Res. Pract. 2008, 204, 511-524
106. Thong-Ngam, D.; Samuhasaneeto, S.; Kulaputana, O.; Klaikeaw, N. N-acetylcysteine attenuates oxidative stress and liver pathology in rats with non-alcoholic steatohepatitis. World J. Gastroenterol. 2007, 13, 5127-5132
107. Lin, P.-C.; Lee, M.-Y.; Wang, W.-S.; Yen, C.-C.; Chao, T.-C.; Hsiao, L.-T.; Yang, M.-H.; Chen, P.-M.; Lin, K.-P.; Chiou, T.-J. N-acetylcysteine has neuroprotective effects against oxaliplatin-based adjuvant chemotherapy in colon cancer patients: Preliminary data. Support. Care Cancer 2006, 14, 484-487
108. Pisani, P.; Parkin, D.M.; Munoz, N.; Ferlay, J. Cancer and infection: Estimates of the attributable fraction in 1990. Cancer Epidemiol. Biomark. Prev. 1997, 6, 387-400.
109. Bitetto, D.; Bortolotti, N.; Falleti, E.; Vescovo, S.; Fabris, C.; Fattovich, G.; Cussigh, A.; Cmet, S.; Fornasiere, E.; Ceriani, E. Vitamin A deficiency is associated with hepatitis C virus chronic infection and with unresponsiveness to interferon-based antiviral therapy. Hepatology 2013, 57, 925-933
110. Mohd Hanafiah, K.; Groeger, J.; Flaxman, A.D.; Wiersma, S.T. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013, 57, 1333-1342
111. Poli, G. Pathogenesis of liver fibrosis: Role of oxidative stress. Mol. Asp. Med. 2000, 21, 49-98
112. Farias, M.S.; Budni, P.; Ribeiro, C.M.; Parisotto, E.B.; Santos, C.E.I.; Dias, J.F.; Dalmarco, E.M.; Fröde, T.S.; Pedrosa, R.C.; Wilhelm Filho, D. Antioxidant supplementation attenuates oxidative stress in chronic hepatitis C patients. Gastroenterol. Hepatol. 2012, 35, 386-394
113. Ko, W.-S.; Guo, C.-H.; Yeh, M.-S.; Lin, L.-Y.; Hsu, G.-S.W.; Chen, P.-C.; Luo, M.-C.; Lin, C.-Y. Blood micronutrient, oxidative stress, and viral load in patients with chronic hepatitis C. World J. Gastroenterol. 2005, 11, 4697-4702
114. Miyanishi, K.; Hoki, T.; Tanaka, S.; Kato, J. Prevention of hepatocellular carcinoma: Focusing on antioxidant therapy. World J. Hepatol. 2015, 7, 593-599
115. Tardif, K.D.; Waris, G.; Siddiqui, A. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol. 2005, 13, 159-163
116. Andrea Moura, F.; Queiroz de Andrade, K.; Celia Farias dos Santos, J.; Oliveira Fonseca Goulart, M. Lipoic acid: Its antioxidant and anti-inflammatory role and clinical applications. Curr. Top. Med. Chem. 2015, 15, 458-483
117. Shedlofsky, S. Role of iron in the natural history and clinical course of hepatitis C disease. Hepato-Gastroenterology 1997, 45, 349-355.
118. Metwally, M.A.; Zein, C.O.; Zein, N.N. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am. J. Gastroenterol. 2004, 99, 286-291
119. Rojas, C.; Matos, B.; Santiago, N.; Reymunde, A.; Matta, J.L. Hepatitis C patients in puerto rico have an altered iron balance. Biol. Trace Element Res. 2001, 84, 239-245
120. Shan, Y.; Lambrecht, R.W.; Bonkovsky, H.L. Association of hepatitis C virus infection with serum iron status: Analysis of data from the third national health and nutrition examination survey. Clin. Infect. Dis. 2005, 40, 834-841
121. Bulatova, I.; Tretyakova, Y.L.; Shchekotov, V.; Shchekotova, A.; Ulitina, P.; Krivtsov, A.; Nenasheva, O.Y. Catalase gene rs1001179 polymorphism and oxidative stress in patients with chronic hepatitis C and ulcerative colitis. Terapevticheskii Arkhiv 2015, 87, 49-53
122. Gabr, S.A.; Alghadir, A.H. Prediction of fibrosis in hepatitis C patients: Assessment using hydroxyproline and oxidative stress biomarkers. Virusdisease 2014, 25, 91-100
123. Trépo, C.; Chan, H.L.; Lok, A. Hepatitis B virus infection. Lancet 2014, 384, 2053-2063
124. McMahon, B.J. Natural history of chronic hepatitis B. Clin. Liver Dis. 2010, 14, 381-396
125. Seiva, F.R.F.; Amauchi, J.F.; Rocha, K.K.R.; Souza, G.A.; Ebaid, G.X.; Burneiko, R.M.; Novelli, E.L.B. Effects of N-acetylcysteine on alcohol abstinence and alcohol-induced adverse effects in rats. Alcohol 2009, 43, 127-135
126. Tong, A.; Wu, L.; Lin, Q.; Lau, Q.C.; Zhao, X.; Li, J.; Chen, P.; Chen, L.; Tang, H.; Huang, C. Proteomic analysis of cellular protein alterations using a hepatitis B virus-producing cellular model. Proteomics 2008, 8, 2012-2023
127. Hajjou, M.; Norel, R.; Carver, R.; Marion, P.; Cullen, J.; Rogler, L.E.; Rogler, C.E. cDNA microarray analysis of HBV transgenic mouse liver identifies genes in lipid biosynthetic and growth control pathways affected by HBV. J. Med. Virol. 2005, 77, 57-65
128. Kim, Y.S.; Seo, H.W.; Jung, G. Reactive oxygen species promote heat shock protein 90-mediated hbv capsid assembly. Biochem. Biophys. Res. Commun. 2015, 457, 328-333
129. Dikici, I.; Mehmetoglu, I.; Dikici, N.; Bitirgen, M.; Kurban, S. Investigation of oxidative stress and some antioxidants in patients with acute and chronic viral hepatitis B and the effect of interferon-α treatment. Clin. Biochem. 2005, 38, 1141-1144
130. Li, H.; Zhu, W.; Zhang, L.; Lei, H.; Wu, X.; Guo, L.; Chen, X.; Wang, Y.; Tang, H. The metabolic responses to hepatitis B virus infection shed new light on pathogenesis and targets for treatment. Sci. Rep. 2015, 5
131. Duygu, F.; Karsen, H.; Aksoy, N.; Taskin, A. Relationship of oxidative stress in hepatitis B infection activity with hbv DNA and fibrosis. Ann. Lab. Med. 2012, 32, 113-118
132. Rehm, J.; Mathers, C.; Popova, S.; Thavorncharoensap, M.; Teerawattananon, Y.; Patra, J. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 2009, 373, 2223-2233
133. O'Shea, R.S.; Dasarathy, S.; McCullough, A.J. Alcoholic liver disease. Hepatology 2010, 51, 307-328
134. Lv, X.; Chen, Z.; Li, J.; Zhang, L.; Liu, H.; Huang, C.; Zhu, P. Caffeine protects against alcoholic liver injury by attenuating inflammatory response and oxidative stress. Inflamm. Res. 2010, 59, 635-645
135. Albano, E. Oxidative mechanisms in the pathogenesis of alcoholic liver disease. Mol. Asp. Med. 2008, 29, 9-16
136. Lu, Z.-M.; Tao, W.-Y.; Xu, H.-Y.; Ao, Z.-H.; Zhang, X.-M.; Xu, Z.-H. Further studies on the hepatoprotective effect of antrodia camphorata in submerged culture on ethanol-induced acute liver injury in rats. Nat. Prod. Res. 2011, 25, 684-695
137. Wu, D.I.; Cederbaum, A.I. Oxidative stress and alcoholic liver disease. Semin. Liver Dis. 2009, 29, 141-154
138. Jimenez-Lopez, J.M.; Cederbaum, A.I. CYP2E1-dependent oxidative stress and toxicity: Role in ethanol-induced liver injury. Expert Opin. Drug Metab. Toxicol. 2005, 1, 671-685
139. Kim, H.K.; Kim, D.-S.; Cho, H.-Y. Protective effects of platycodi radix on alcohol-induced fatty liver. Biosci. Biotechnol. Biochem. 2007, 71, 1550-1552
140. Lian, L.-H.; Wu, Y.-L.; Song, S.-Z.; Wan, Y.; Xie, W.-X.; Li, X.; Bai, T.; Ouyang, B.-Q.; Nan, J.-X. Gentiana manshurica kitagawa reverses acute alcohol-induced liver steatosis through blocking sterol regulatory element-binding protein-1 maturation. J. Agric. Food Chem. 2010, 58, 13013-13019
141. Yao, P.; Li, K.; Song, F.; Zhou, S.; Sun, X.; Zhang, X.; Nüssler, A.K.; Liu, L. Heme oxygenase-1 upregulated by ginkgo biloba extract: Potential protection against ethanol-induced oxidative liver damage. Food Chem. Toxicol. 2007, 45, 1333-1342
142. Radosavljević, T.; Mladenović, D.; Vučević, D. The role of oxidative stress in alcoholic liver injury. Med. Pregled 2009, 62, 547-553
143. Kaviarasan, S.; Sundarapandiyan, R.; Anuradha, C. Protective action of fenugreek (Trigonella foenum graecum) seed polyphenols against alcohol-induced protein and lipid damage in rat liver. Cell Biol. Toxicol. 2008, 24, 391-400
144. Zhao, M.; Du, Y.-Q.; Yuan, L.; Wang, N.-N. Protective effect of puerarin on acute alcoholic liver injury. Am. J. Chin. Med. 2010, 38, 241-249
145. Yuan, G.; Gong, Z.; Li, J.; Li, X. Ginkgo biloba extract protects against alcohol-induced liver injury in rats. Phytother. Res. 2007, 21, 234-238
146. Samuhasaneeto, S.; Thong-Ngam, D.; Kulaputana, O.; Suyasunanont, D.; Klaikeaw, N. Curcumin decreased oxidative stress, inhibited NF-κB activation, and improved liver pathology in ethanol-induced liver injury in rats. J. Biomed. Biotechnol. 2009, 2009
147. Bharrhan, S.; Koul, A.; Chopra, K.; Rishi, P.; Lee, T. Catechin suppresses an array of signalling molecules and modulates alcohol-induced endotoxin mediated liver injury in a rat model. PLoS ONE 2011, 6, e20635
148. Rao, R.K.; Seth, A.; Sheth, P.; Rao, P. Recent advances in alcoholic liver disease. I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am. J. Physiol. Gastrointest. Liver Physiol. 2004, 286, G881-G884
149. Zhang, R.; Hu, Y.; Yuan, J.; Wu, D. Effects of puerariae radix extract on the increasing intestinal permeability in rat with alcohol-induced liver injury. J. Ethnopharmacol. 2009, 126, 207-214
150. Hritz, I.; Mandrekar, P.; Velayudham, A.; Catalano, D.; Dolganiuc, A.; Kodys, K.; Kurt-Jones, E.; Szabo, G. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology (Baltim. Md.) 2008, 48, 1224-1231
151. Yin, M.; Bradford, B.U.; Wheeler, M.D.; Uesugi, T.; Froh, M.; Goyert, S.M.; Thurman, R.G. Reduced early alcohol-induced liver injury in CD14-deficient mice. J. Immunol. 2001, 166, 4737-4742
152. Yoon, S.-J.; Koh, E.-J.; Kim, C.-S.; Zee, O.-P.; Kwak, J.-H.; Jeong, W.-J.; Kim, J.-H.; Lee, S.-M. Agrimonia eupatoria protects against chronic ethanol-induced liver injury in rats. Food Chem. Toxicol. 2012, 50, 2335-2341
153. Kanuri, G.; Weber, S.; Volynets, V.; Spruss, A.; Bischoff, S.C.; Bergheim, I. Cinnamon extract protects against acute alcohol-induced liver steatosis in mice. J. Nutr. 2009, 139, 482-487
154. Kim, S.-J.; Lee, S.-M. Effect of baicalin on toll-like receptor 4-mediated ischemia/reperfusion inflammatory responses in alcoholic fatty liver condition. Toxicol. Appl. Pharmacol. 2012, 258, 43-50
155. Nanji, A.; Jokelainen, K.; Tipoe, G.; Rahemtulla, A.; Thomas, P.; Dannenberg, A. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-κB-dependent genes. Am. J. Physiol. Gastrointest. Liver Physiol. 2003, 284, G321-G327
156. Neuman, M.G. Cytokines-central factors in alcoholic liver disease. Alcohol Res. Health J. Natl. Inst. Alcohol Abuse Alcohol. 2003, 27, 307-316.
157. Thurman, R.G. Mechanisms of hepatic toxicity II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. Am. J. Physiol. Gastrointest. Liver Physiol. 1998, 38, G605-G611.
158. Purohit, V.; Gao, B.; Song, B.J. Molecular mechanisms of alcoholic fatty liver. Alcohol. Clin. Exp. Res. 2009, 33, 191-205
159. You, M.; Crabb, D.W. Molecular mechanisms of alcoholic fatty liver: Role of sterol regulatory element-binding proteins. Alcohol 2004, 34, 39-43
160. Horton, J.D.; Goldstein, J.; Brown, M.S. Srebps: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 2002, 109, 1125-1131
161. Yin, H.Q.; Kim, Y.C.; Chuang, Y.S.; Kim, Y.C.; Shin, Y.K.; Lee, B.H. Honokiol reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element binding protein-1c and the expression of its downstream lipogenesis genes. Toxicol. Appl. Pharmacol. 2009, 236, 124-130
162. Chen, K.-H.; Li, P.-C.; Lin, W.-H.; Chien, C.-T.; Low, B.-H. Depression by a green tea extract of alcohol-induced oxidative stress and lipogenesis in rat liver. Biosci. Biotechnol. Biochem. 2011, 75, 1668-1676
163. Ajmo, J.M.; Liang, X.; Rogers, C.Q.; Pennock, B.; You, M. Resveratrol alleviates alcoholic fatty liver in mice. Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 295, G833-G842
164. Yin, H.-Q.; Je, Y.-T.; Kim, Y.-C.; Shin, Y.-K.; Sung, S.; Lee, K.; Lee, B.-H.; Jeong, G.-S.; Kim, Y.-C. Magnolia officinalis reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element-binding protein-1c. J. Pharmacol. Sci. 2009, 109, 486-495
165. Long, Y.C.; Zierath, J.R. AMP-activated protein kinase signaling in metabolic regulation. J. Clin. Investig. 2006, 116, 1776-1783
166. Endo, M.; Masaki, T.; Seike, M.; Yoshimatsu, H. TNF-α induces hepatic steatosis in mice by enhancing gene expression of sterol regulatory element binding protein-1c (SREBP-1c). Exp. Biol. Med. 2007, 232, 614-621.
167. Lawler, J.F., Jr.; Yin, M.; Diehl, A.M.; Chatterjee, S.; Roberts, E. Tumor necrosis factor-α stimulates the maturation of sterol regulatory element binding protein-1 in human hepatocytes through the action of neutral sphingomyelinase. J. Biol. Chem. 1998, 273, 5053-5059
168. Lagouge, M.; Argmann, C.; Gerhart-Hines, Z.; Meziane, H.; Lerin, C.; Daussin, F.; Messadeq, N.; Milne, J.; Lambert, P.; Elliott, P.; et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell 2006, 127, 1109-1122
169. Wada, S.; Yamazaki, T.; Kawano, Y.; Miura, S.; Ezaki, O. Fish oil fed prior to ethanol administration prevents acute ethanol-induced fatty liver in mice. J. Hepatol. 2008, 49, 441-450
170. Grasselli, E.; Compalati, A.D.; Voci, A.; Vecchione, G.; Ragazzoni, M.; Gallo, G.; Borro, P.; Sumberaz, A.; Testino, G.; Vergani, L. Altered oxidative stress/antioxidant status in blood of alcoholic subjects is associated with alcoholic liver disease. Drug Alcohol Depend. 2014, 143, 112-119
171. Vernon, G.; Baranova, A.; Younossi, Z. Systematic review: The epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment. Pharmacol. Ther. 2011, 34, 274-285
172. Day, C.P.; James, O.F. Steatohepatitis: A tale of two "HITS"? Gastroenterology 1998, 114, 842-845
173. de Medeiros, I.C.; de Lima, J.G. Is nonalcoholic fatty liver disease an endogenous alcoholic fatty liver disease?-A mechanistic hypothesis. Med. Hypotheses 2015, 85, 148-152
174. Houstis, N.; Rosen, E.D.; Lander, E.S. Reactive oxygen species have a causal role in multiple forms of insulin resistance. Nature 2006, 440, 944-948
175. Al Rifai, M.; Silverman, M.G.; Nasir, K.; Budoff, M.J.; Blankstein, R.; Szklo, M.; Katz, R.; Blumenthal, R.S.; Blaha, M.J. The association of nonalcoholic fatty liver disease, obesity, and metabolic syndrome, with systemic inflammation and subclinical atherosclerosis: The multi-ethnic study of atherosclerosis (MESA). Atherosclerosis 2015, 239, 629-633
176. Ozenirler, S.; Erkan, G.; Konca Degertekin, C.; Ercin, U.; Cengiz, M.; Bilgihan, A.; Yilmaz, G.; Akyol, G. The relationship between advanced oxidation protein products (AOPP) and biochemical and histopathological findings in patients with nonalcoholic steatohepatitis. J. Dig. Dis. 2014, 15, 131-136
177. Sayre, L.M.; Lin, D.; Yuan, Q.; Zhu, X.; Tang, X. Protein adducts generated from products of lipid oxidation: Focus on hne and one*. Drug Metab. Rev. 2006, 38, 651-675
178. Farhangi, M.A.; Alipour, B.; Jafarvand, E.; Khoshbaten, M. Oral coenzyme q10 supplementation in patients with nonalcoholic fatty liver disease: Effects on serum vaspin, chemerin, pentraxin 3, insulin resistance and oxidative stress. Arch. Med. Res. 2014, 45, 589-595
179. Horoz, M.; Bolukbas, C.; Bolukbas, F.F.; Sabuncu, T.; Aslan, M.; Sarifakiogullari, S.; Gunaydin, N.; Erel, O. Measurement of the total antioxidant response using a novel automated method in subjects with nonalcoholic steatohepatitis. BMC Gastroenterol. 2005, 5
180. Koruk, M.; Taysi, S.; Savas, M.C.; Yilmaz, O.; Akcay, F.; Karakok, M. Oxidative stress and enzymatic antioxidant status in patients with nonalcoholic steatohepatitis. Ann. Clin. Lab. Sci. 2004, 34, 57-62
181. Chen, M.; Suzuki, A.; Borlak, J.; Andrade, R.J.; Lucena, M.I. Drug-induced liver injury: Interactions between drug properties and host factors. J. Hepatol. 2015, 63, 503-514
182. Tan, C.Y.; Saw, T.Y.; Fong, C.W.; Ho, H.K. Comparative hepatoprotective effects of tocotrienol analogs against drug-induced liver injury. Redox Biol. 2015, 4, 308-320
183. Mathurin, P.; Hadengue, A.; Bataller, R.; Addolorato, G.; Burra, P.; Burt, A.; Caballeria, J.; Cortez-Pinto, H.; Day, C.P.; Forrest, E.H. EASL clinical practical guidelines: Management of alcoholic liver disease. J. Hepatol. 2012, 57, 399-420
184. Imperiale, T.F.; McCullough, A.J. Do corticosteroids reduce mortality from alcoholic hepatitis?: A meta-analysis of the randomized trials. Ann. Intern. Med. 1990, 113, 299-307
185. Louvet, A.; Wartel, F.; Castel, H.; Dharancy, S.; Hollebecque, A.; Canva-Delcambre, V.; Deltenre, P.; Mathurin, P. Infection in patients with severe alcoholic hepatitis treated with steroids: Early response to therapy is the key factor. Gastroenterology 2009, 137, 541-548
186. Lebrec, D.; Thabut, D.; Oberti, F.; Perarnau, J.M.; Condat, B.; Barraud, H.; Saliba, F.; Carbonell, N.; Renard, P.; Ramond, M.J. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. Gastroenterology 2010, 138, 1755-1762
187. De, B.K.; Gangopadhyay, S.; Dutta, D.; Baksi, S.D.; Pani, A.; Ghosh, P. Pentoxifylline versus prednisolone for severe alcoholic hepatitis: A randomized controlled trial. World J. Gastroenterol. 2009, 15, 1613-1619
188. Gao, B. Hepatoprotective and anti-inflammatory cytokines in alcoholic liver disease. J. Gastroenterol. Hepatol. 2012, 27, 89-93
189. Park, O.; Wang, H.; Weng, H.; Feigenbaum, L.; Li, H.; Yin, S.; Ki, S.H.; Yoo, S.H.; Dooley, S.; Wang, F.S. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology 2011, 54, 252-261
190. Ren, X.; Hu, B.; Colletti, L.M. IL-22 is involved in liver regeneration after hepatectomy. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G74-G80
191. Aujla, S.; Kolls, J. IL-22: A critical mediator in mucosal host defense. J. Mol. Med. 2009, 87, 451-454
192. Luo, P.; Wang, M.-H. Eicosanoids, β-cell function, and diabetes. Prostaglandins Other Lipid Mediat. 2011, 95, 1-10
193. Rafieian-Kopaei, M.; Baradaran, A.; Rafieian, M. Oxidative stress and the paradoxical effects of antioxidants. J. Res. Med. Sci. 2013, 18, 628
194. Miller, E.R.; Pastor-Barriuso, R.; Dalal, D.; Riemersma, R.A.; Appel, L.J.; Guallar, E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142, 37-46
195. Greenland, S. Weaknesses of bayesian model averaging for meta-analysis in the study of vitamin E and mortality. Clin. Trials 2009, 6, 42-46
196. Nasri, H.; Rafieian-Kopaei, M. Medicinal plants and antioxidants: Why they are not always beneficial? Iran. J. Public Health 2014, 43, 255-257
197. Hajian, S.; Rafieian-Kopaei, M.; Nasri, H. Renoprotective effects of antioxidants against cisplatin nephrotoxicity. J. Nephropharmacol. 2015, 3, 39-42.
198. Madihi, Y.; Merrikhi, A.; Baradaran, A.; Rafieian-Kopaei, M.; Shahinfard, N.; Ansari, R.; Shirzad, H.; Mesripour, A. Impact of sumac on postprandialhigh-fat oxidative stress. 2013, 29
199. Karimi, A.; Majlesi, M.; Rafieian-Kopaei, M. Herbal versus synthetic drugs; beliefs and facts. J. Nephropharmacol. 2015, 4, 27-30.
200. Baradaran, A.; Nasri, H.; Rafieian-Kopaei, M. Oxidative stress and hypertension: Possibility of hypertension therapy with antioxidants. J. Res. Med. Sci. Off. J. Isfahan Univ. Med. Sci. 2014, 19, 358-367.
201. Hajivandi, A.; Amiri, M. World kidney day 2014: Kidney disease and elderly. J. Parathyr. Dis. 2015, 2, 3-4.
202. Rafieian-Kopaei, M.; Baradaran, A. Teucrium polium and kidney. J. Renal Inj. Prev. 2013, 2, 3-4
203. Tamadon, M.-R.; Ardalan, M.-R.; Nasri, H. World kidney day 2013; acute renal injury; a global health warning. J. Parathyr. Dis. 2015, 1, 27-28.
204. Hulbert, A.J.; Turner, N.; Storlien, L.; Else, P. Dietary fats and membrane function: Implications for metabolism and disease. Biol. Rev. 2005, 80, 155-169
205. Baradaran, A.; Nasri, H.; Nematbakhsh, M.; Rafieian-Kopaei, M. Antioxidant activity and preventive effect of aqueous leaf extract of aloe vera on gentamicin-induced nephrotoxicity in male wistar rats. La Clin. Ter. 2013, 165, 7-11.
206. Rafieian-Kopaei, M.; Motamedi, P.; Vakili, L.; Dehghani, N.; Kiani, F.; Taheri, Z.; Torkamaneh, S.; Nasri, P.; Nasri, H. Green tea and type 2 diabetes mellitus. J. Nephropharmacol. 2015, 3, 21-23.
207. Nasri, H.; Shirzad, H. Toxicity and safety of medicinal plants. J. HerbMed Plarmacol. 2013, 2, 21-22.
208. Mogharabi, M.; Abdollahi, M.; Faramarzi, M.A. Safety concerns to application of graphene compounds in pharmacy and medicine. Daru 2014, 22(1), 22-23
209. Bernstein, B.E.; Meissner, A.; Lander, E.S. The mammalian epigenome. Cell 2007, 128, 669-681
210. Landgraf, P.; Rusu, M.; Sheridan, R.; Sewer, A.; Iovino, N.; Aravin, A.; Pfeffer, S.; Rice, A.; Kamphorst, A.O.; Landthaler, M.; et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007, 129, 1401-1414
211. Fuks, F. DNA methylation and histone modifications: Teaming up to silence genes. Curr. Opin. Genet. Dev. 2005, 15, 490-495
212. Kim, D.H.; Saetrom, P.; Snøve, O.; Rossi, J.J. MicroRNA-directed transcriptional gene silencing in mammalian cells. Proc. Natl. Acad. Sci. USA 2008, 105, 16230-16235
213. Baccarelli, A.; Bollati, V. Epigenetics and environmental chemicals. Curr. Opin. Pediatr. 2009, 21, 243-251
214. Hudder, A.; Novak, R.F. Mirnas: Effectors of environmental influences on gene expression and disease. Toxicol. Sci. 2008, 103, 228-240
215. Hewagama, A.; Richardson, B. The genetics and epigenetics of autoimmune diseases. J. Autoimmun. 2009, 33, 3-11
216. Yang, B.; Lin, H.; Xiao, J.; Lu, Y.; Luo, X.; Li, B.; Zhang, Y.; Xu, C.; Bai, Y.; Wang, H.; et al. The muscle-specific microrna miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat. Med. 2007, 13, 486-491
217. Wang, S.-C.; Oelze, B.; Schumacher, A. Age-specific epigenetic drift in late-onset Alzheimer’s disease. PLoS ONE 2008, 3, e2698
218. Andrew, P.F.; Rolf, O.; Steven, H. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 2006, 7, 21-33.
219. Zhang, X. The epigenetic landscape of plants. Science 2008, 320, 489-492
220. Maccani, M.A.; Marsit, C.J. Review Article: Epigenetics in the Placenta. Am. J. Reprod. Immunol. 2009, 62, 78-89
221. Johnson, I.T.; Belshaw, N.J. Environment, diet and CPG island methylation: Epigenetic signals in gastrointestinal neoplasia. Food Chem. Toxicol. 2008, 46, 1346-1359
222. François, F.; Wendy, A.B.; Alexander, B.; Luke, H.-D.; Tony, K. DNA methyltransferase DNMT1 associates with histone deacetylase activity. Nat. Genet. 2000, 24, 88-91.
223. Hsieh, H.-Y.; Chiu, P.-H.; Wang, S.-C. Epigenetics in traditional chinese pharmacy: A bioinformatic study at pharmacopoeia scale. Evid. Based Complement. Altern. Med. 2011, 2011
224. Veerle, R.; Anders, M.N. MicroRNAs in metabolism and metabolic disorders. Nat. Rev. Mol. Cell Biol. 2012, 13, 239-250.
225. Szabo, G.; Sarnow, P.; Bala, S. MicroRNA silencing and the development of novel therapies for liver disease. J. Hepatol. 2012, 57, 462-466
226. Machlin, E.; Sarnow, P.; Sagan, S.M. Combating hepatitis C virus by targeting microrna-122 using locked nucleic acids. Curr. Gene Ther. 2012, 12, 301-306
227. Lanford, R.E.; Hildebrandt-Eriksen, E.S.; Petri, A.; Persson, R.; Lindow, M.; Munk, M.E.; Kauppinen, S.; Ørum, H. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 2010, 327, 198-201
228. Feng, D.; Liu, T.; Sun, Z.; Bugge, A.; Mullican, S.E.; Alenghat, T.; Liu, X.S.; Lazar, M.A. A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid metabolism. Science 2011, 331, 1315-1319
229. Zheng, S.; Russell, A.M.; Rajesh, T.P.; Jie, C.; Ravindra, D.; Hong, W.; Dongyan, Z.; Mark, J.G.; Terry, G.U.; Gerald, I.S.; et al. Hepatic HDAC3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat. Med. 2012, 18, 934-942.
230. Yang, M.D.; Chiang, Y.M.; Higashiyama, R.; Asahina, K.; Mann, D.A.; Mann, J.; Wang, C.C.; Tsukamoto, H. Rosmarinic acid and baicalin epigenetically derepress peroxisomal proliferator-activated receptor γ in hepatic stellate cells for their antifibrotic effect. Hepatology 2012, 55, 1271-1281
231. Akbar, S. Andrographis paniculata: A review of pharmacological activities and clinical effects. Altern. Med. Rev. 2011, 16, 66-77
232. Wagner, H.; Bauer, R.; Melchart, D.; Xiao, P.-G.; Staudinger, A. Chromatographic Fingerprint Analysis of Herbal Medicines; Springer: Berlin, Germany, 2011.
233. Girish, C.; Koner, B.; Jayanthi, S.; Rao, K.; Rajesh, B.; Pradhan, S. Hepatoprotective activity of six polyherbal formulations in paracetamol induced liver toxicity in mice. Indian J. Med. Res. 2009, 129, 569-578
234. Handa, S.; Sharma, A.; Chakraborti, K. Natural products and plants as liver protecting drugs. Fitoterapia 1986, 57, 307-351.
235. Kapil, A.; Koul, I.; Banerjee, S.; Gupta, B. Antihepatotoxic effects of major diterpenoid constituents of Andrographis paniculata. Biochem. Pharmacol. 1993, 46, 182-185
236. Jarukamjorn, K.; Nemoto, N. Pharmacological aspects of Andrographis paniculata on health and its major diterpenoid constituent andrographolide. J. Health Sci. 2008, 54, 370-381
237. Vetriselvan, S.; Subasini, U.; Rajamanickam, C.; Thirumurugu, S. Hepatoprotective activity of Andrographis paniculata in ethanol induced hepatotoxicity in albino wistar rats. Pharm. Glob. 2011, 2, 1-4.
238. Trivedi, N.; Rawal, U. Hepatoprotective and toxicological evaluation of Andrographis paniculata on severe liver damage. Indian J. Pharmacol. 2000, 32, 288-293.
239. Hidalgo, M.A.; Romero, A.; Figueroa, J.; Cortés, P.; Concha, I.I.; Hancke, J.L.; Burgos, R.A. Andrographolide interferes with binding of nuclear factor-κB to DNA in HL-60-derived neutrophilic cells. Br. J. Pharmacol. 2005, 144, 680-686
240. Shen, Y.C.; Chen, C.F.; Chiou, W.F. Andrographolide prevents oxygen radical production by human neutrophils: Possible mechanism(s) involved in its anti-inflammatory effect. Br. J. Pharmacol. 2002, 135, 399-406
241. Visen, P.K.; Saraswat, B.; Vuksan, V.; Dhawan, B. Effect of andrographolide on monkey hepatocytes against galactosamine induced cell toxicity: An in vitro study. J. Complement. Integr. Med. 2007, 4
242. Yoshikawa, M.; Ninomiya, K.; Shimoda, H.; Nishida, N.; Matsuda, H. Hepatoprotective and antioxidative properties of salacia reticulata: Preventive effects of phenolic constituents on CCL4-induced liver injury in mice. Biol. Pharm. Bull. 2002, 25, 72-76
243. Prakash, E.L. Evaluation of in vitro antioxidant activity of leaf extract of Andrographis paniculata. Res. J. Pharm. Biol. Chem. Sci. 2011, 2, 891-895.
244. Parichatikanond, W.; Suthisisang, C.; Dhepakson, P.; Herunsalee, A. Study of anti-inflammatory activities of the pure compounds from Andrographis paniculata (Burm. F.) nees and their effects on gene expression. Int. Immunopharmacol. 2010, 10, 1361-1373
245. Lim, J.C.W.; Chan, T.K.; Ng, D.S.; Sagineedu, S.R.; Stanslas, J.; Wong, W. Andrographolide and its analogues: Versatile bioactive molecules for combating inflammation and cancer. Clin. Exp. Pharmacol. Physiol. 2012, 39, 300-310
246. Panossian, A.; Davtyan, T.; Gukassyan, N.; Gukasova, G.; Mamikonyan, G.; Gabrielian, E.; Wikman, G. Effect of andrographolide and Kan Jang-Fixed combination of extract SHA-10 and extract SHE-3-On proliferation of human lymphocytes, production of cytokines and immune activation markers in the whole blood cells culture. Phytomedicine 2002, 9, 598-605
247. See, D.; Mason, S.; Roshan, R. Increased tumor necrosis factor α (TNF-α) and natural killer cell (NK) function using an integrative approach in late stage cancers. Immunol. Investig. 2002, 31, 137-153
248. Xia, Y.-F.; Ye, B.-Q.; Li, Y.-D.; Wang, J.-G.; He, X.-J.; Lin, X.; Yao, X.; Ma, D.; Slungaard, A.; Hebbel, R.P. Andrographolide attenuates inflammation by inhibition of NF-κB activation through covalent modification of reduced cysteine 62 of p50. J. Immunol. 2004, 173, 4207-4217
249. Bao, Z.; Guan, S.; Cheng, C.; Wu, S.; Wong, S.H.; Kemeny, D.M.; Leung, B.P.; Wong, W.F. A novel antiinflammatory role for andrographolide in asthma via inhibition of the nuclear factor-κB pathway. Am. J. Respir. Crit. Care Med. 2009, 179, 657-665
250. Chao, W.-W.; Kuo, Y.-H.; Li, W.-C.; Lin, B.-F. The production of nitric oxide and prostaglandin E2 in peritoneal macrophages is inhibited by Andrographis paniculata, angelica sinensis and morus alba ethyl acetate fractions. J. Ethnopharmacol. 2009, 122, 68-75
251. Chao, W.-W.; Lin, B.-F. Review isolation and identification of bioactive compounds in Andrographis paniculata (chuanxinlian). Growth 2010, 10
252. Chao, W.-W.; Kuo, Y.-H.; Hsieh, S.-L.; Lin, B.-F. Inhibitory effects of ethyl acetate extract of Andrographis paniculata on NF-κB trans-activation activity and LPS-induced acute inflammation in mice. Evid. Based Complement. Altern. Med. 2011, 2011
253. Lien, L.M.; Su, C.C.; Hsu, W.H.; Lu, W.J.; Chung, C.L.; Yen, T.L.; Chiu, H.C.; Sheu, J.R.; Lin, K.H. Mechanisms of andrographolide-induced platelet apoptosis in human platelets: Regulatory roles of the extrinsic apoptotic pathway. Phytother. Res. 2013, 27, 1671-1677
254. Chiou, W.F.; Chen, C.F.; Lin, J.J. Mechanisms of suppression of inducible nitric oxide synthase (iNOS) expression in RAW 264.7 cells by andrographolide. Br. J. Pharmacol. 2000, 129, 1553-1560
255. Wang, T.; Liu, B.; Zhang, W.; Wilson, B.; Hong, J.-S. Andrographolide reduces inflammation-mediated dopaminergic neurodegeneration in mesencephalic neuron-glia cultures by inhibiting microglial activation. J. Pharmacol. Exp. Ther. 2004, 308, 975-983
256. Chiou, W.F.; Lin, J.J.; Chen, C.F. Andrographolide suppresses the expression of inducible nitric oxide synthase in macrophage and restores the vasoconstriction in rat aorta treated with lipopolysaccharide. Br. J. Pharmacol. 1998, 125, 327-334
257. Marı, M.; Cederbaum, A.I. Induction of catalase, α, and microsomal glutathione s-transferase in CYP2E1 overexpressing HepG2 cells and protection against short-term oxidative stress. Hepatology 2001, 33, 652-661
258. Zhou, Z.; Sun, X.; James Kang, Y. Metallothionein protection against alcoholic liver injury through inhibition of oxidative stress. Exp. Biol. Med. 2002, 227, 214-222.
259. Adamska, T.; Młynarczyk, W.; Jodynis-liebert, J.; Bylka, W.; Matławska, I. Hepatoprotective effect of the extract and isocytisoside from aquilegia vulgaris. Phytother. Res. 2003, 17, 691-696
260. Dobrzy nska, I.; Figaszewski, Z.; Snieci nska, A.; Skrzydlewska, E. Green tea modulation of the biochemical and electric properties of rat liver cells that were affected by ethanol and aging. Cell. Mol. Biol. Lett. 2004, 9, 709-721
261. Molina, M.F.; Iglesias, I.; Benedi, J.; Sanchez-Reus, I. Quercetin, a flavonoid antioxidant, prevents and protects against ethanol-induced oxidative stress in mouse liver. Biol. Pharm. Bull. 2003, 26, 1398-1402
262. Ozaras, R.; Tahan, V.; Aydin, S.; Uzun, H.; Kaya, S.; Senturk, H. N-acetylcysteine attenuates alcohol-induced oxidative stess in rats. World J. Gastroenterol. 2003, 9, 791-794
263. Uzun, H.; Aydin, S.; Kaya, S.; Simsek, G.; Yelmen, N.K.; Unal, E.; Karter, Y.; Curgunlu, A.; Vehid, S. Potential effects of L-NAME on alcohol-induced oxidative stress. World J. Gastroenterol. 2005, 11, 600-604
264. Das, S.; Gautam, N.; Dey, S.K.; Maiti, T.; Roy, S. Oxidative stress in the brain of nicotine-induced toxicity: Protective role of Andrographis paniculata nees and vitamin e. Appl. Physiol. Nutr. Metab. 2009, 34, 124-135
265. Lin, F.; Wu, S.; Lee, S.; Ng, L. Antioxidant, antioedema and analgesic activities of Andrographis paniculata extracts and their active constituent andrographolide. Phytother. Res. 2009, 23, 958-964
266. Bold, R.; Termuhlen, P.; McConkey, D. Apoptosis, cancer and cancer therapy. Surg. Oncol. Oxf. 1997, 6, 133-142
267. Yam, M.F.; Ang, L.F.; Lim, C.P.; Ameer, O.Z.; Salman, I.M.; Ahmad, M.; Mohammed, M.A.-M.; Asmawi, M.Z.; Abdulkarim, M.F.; Abdullah, G.Z. Antioxidant and hepatoprotective effects of murdannia bracteata methanol extract. JAMS J. Acupunct. Meridian Stud. 2010, 3, 197-202
268. Yang, T.; Shi, H.X.; Wang, Z.T.; Wang, C.H. Hypolipidemic effects of andrographolide and neoandrographolide in mice and rats. Phytother. Res. 2013, 27, 618-623
269. Yanpallewar, S.U.; Sen, S.; Tapas, S.; Kumar, M.; Raju, S.S.; Acharya, S.B. Effect of azadirachta indica on paracetamol-induced hepatic damage in albino rats. Phytomedicine 2003, 10, 391-396
270. Asha, V.V.; Akhila, S.; Wills, P.J.; Subramoniam, A. Further studies on the antihepatotoxic activity of phyllanthus maderaspatensis LINN. J. Ethnopharmacol. 2004, 92, 67-70
271. Maiti, K.; Mukherjee, K.; Murugan, V.; Saha, B.P.; Mukherjee, P.K. Enhancing bioavailability and hepatoprotective activity of andrographolide from Andrographis paniculata, a well-known medicinal food, through its herbosome. J. Sci. Food Agric. 2010, 90, 43-51
272. Hanje, A.J.; Fortune, B.; Song, M.; Hill, D.; McClain, C. The use of selected nutrition supplements and complementary and alternative medicine in liver disease. Nutr. Clin. Pract. 2006, 21, 255-272
273. Arase, Y.; Ikeda, K.; Murashima, N.; Chayama, K.; Tsubota, A.; Koida, I.; Suzuki, Y.; Saitoh, S.; Kobayashi, M.; Kumada, H. The long term efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997, 79, 1494-1500
274. Wang, C.-Y.; Kao, T.-C.; Lo, W.-H.; Yen, G.-C. Glycyrrhizic acid and 18β-glycyrrhetinic acid modulate lipopolysaccharide-induced inflammatory response by suppression of NF-κB through PI3K p110δ and p110γ inhibitions. J. Agric. Food Chem. 2011, 59, 7726-7733
275. Thiyagarajan, P.; Chandrasekaran, C.; Deepak, H.; Agarwal, A. Modulation of lipopolysaccharide-induced pro-inflammatory mediators by an extract of Glycyrrhiza glabra and its phytoconstituents. Inflammopharmacology 2011, 19, 235-241
276. Li, X.-L.; Zhou, A.-G. Evaluation of the immunity activity of glycyrrhizin in AR mice. Molecules 2012, 17, 716-727
277. Feng, C.; Wang, H.; Yao, C.; Zhang, J.; Tian, Z. Diammonium glycyrrhizinate, a component of traditional Chinese medicine Gan-Cao, prevents murine T-cell-mediated fulminant hepatitis in IL-10-and IL-6-dependent manners. Int. Immunopharmacol. 2007, 7, 1292-1298
278. Lee, C.-H.; Park, S.-W.; Kim, Y.S.; Kang, S.S.; Kim, J.A.; Lee, S.H.; Lee, S.-M. Protective mechanism of glycyrrhizin on acute liver injury induced by carbon tetrachloride in mice. Biol. Pharm. Bull. 2007, 30, 1898-1904
279. Guo, H.-X.; Liu, D.-H.; Ma, Y.; Liu, J.-F.; Wang, Y.; Du, Z.-Y.; Wang, X.; Shen, J.-K.; Peng, H.-L. Long-term baicalin administration ameliorates metabolic disorders and hepatic steatosis in rats given a high-fat diet. Acta Pharmacol. Sin. 2009, 30, 1505-1512
280. Van Rossum, T.; Vulto, A.G.; De Man, R.; Brouwer, J.; Schalm, S. Review article: Glycyrrhizin as a potential treatment for chronic hepatitis C. Aliment. Pharmacol. Ther. 1998, 12, 199-205
281. Wang, J.; Guo, J.; Liu, S. [inhibitory effect of glycyrrhizin on NF-κB binding activity in CCL4 plus ethanol induced liver cirrhosis in rats]. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chin. J. Hepatol. 1999, 7, 42-43.
282. Acharya, S.K.; Dasarathy, S.; Tandon, A.; Joshi, Y.K.; Tandon, B.N. A preliminary open trial on interferon stimulator (SNMC) derived from Glycyrrhiza glabra in the treatment of subacute hepatic failure. Indian J. Med. Res. 1993, 98, 69-74
283. Tekla, G.J.V.R.; Arnold, G.V.; Wim, C.J.H.; Solko, W.S. Glycyrrhizin-induced reduction of alt in european patients with chronic hepatitis C. Am. J. Gastroenterol. 2001, 96, 2432-2437.
284. Kageyama, Y.; Suzuki, H.; Saruta, T. Renin-dependency of glycyrrhizin-induced pseudoaldosteronism. Endocrinol. Jpn. 1991, 38, 103-108
285. Krähenbühl, S.; Hasler, F.; Krapf, R. Analysis and pharmacokinetics of glycyrrhizic acid and glycyrrhetinic acid in humans and experimental animals. Steroids 1994, 59, 121-126
286. Huu Tung, N.; Uto, T.; Morinaga, O.; Kim, Y.H.; Shoyama, Y. Pharmacological effects of ginseng on liver functions and diseases: A minireview. Evid. Based Complement. Altern. Med. 2012, 2012
287. Yang, L.; Deng, Y.; Xu, S.; Zeng, X. In vivo pharmacokinetic and metabolism studies of ginsenoside rd. J. Chromatogr. B 2007, 854, 77-84
288. Cho, W.C.; Chung, W.-S.; Lee, S.K.; Leung, A.W.; Cheng, C.H.; Yue, K.K. Ginsenoside re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2006, 550, 173-179
289. Yokozawa, T.; Kobayashi, T.; Oura, H.; Kawashima, Y. Hyperlipemia-improving effects of ginsenoside-Rb2 in streptozotocin-diabetic rats. Chem. Pharm. Bull. 1985, 33, 3893-3898
290. Song, S.B.; Tung, N.H.; Quang, T.H.; Ngan, N.T.T.; Kim, K.E.; Kim, Y.H. Inhibition of TNF-α-mediated NF-κB transcriptional activity in HepG2 cells by dammarane-type saponins from Panax ginseng leaves. J. Ginseng Res. 2012, 36, 146-152
291. Zhu, J.; Jiang, Y.; Wu, L.; Lu, T.; Xu, G.; Liu, X. Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia. Neuroscience 2012, 202, 342-351
292. Park, E.-K.; Choo, M.-K.; Han, M.J.; Kim, D.-H. Ginsenoside Rh1 possesses antiallergic and anti-inflammatory activities. Int. Arch. Allergy Immunol. 2004, 133, 113-120
293. Chen, X.-C.; Zhu, Y.-G.; Zhu, L.-A.; Huang, C.; Chen, Y.; Chen, L.-M.; Fang, F.; Zhou, Y.-C.; Zhao, C.-H. Ginsenoside Rg1 attenuates dopamine-induced apoptosis in PC12 cells by suppressing oxidative stress. Eur. J. Pharmacol. 2003, 473, 1-7
294. Chen, H.; Yoshioka, H.; Kim, G.; Jung, J.; Okami, N.; Sakata, H.; Maier, C.M.; Narasimhan, P.; Goeders, C.E.; Chan, P. Oxidative stress in ischemic brain damage: Mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid. Redox Signal. 2011, 14, 1505-1517
295. Nabavi, S.M.; Daglia, M.; Moghaddam, A.H.; Nabavi, S.F.; Curti, V. Tea consumption and risk of ischemic stroke: A brief review of the literature. Curr. Pharm. Biotechnol. 2014, 15, 298-303
296. Gillis, C.N. Panax ginseng pharmacology: A nitric oxide link? Biochem. Pharmacol. 1997, 54, 1-8
297. He, F.; Guo, R.; Wu, S.-L.; Sun, M.; Li, M. Protective effects of ginsenoside Rb1 on human umbilical vein endothelial cells in vitro. J. Cardiovasc. Pharmacol. 2007, 50, 314-320
298. Kim, Y.-M.; Namkoong, S.; Yun, Y.-G.; Hong, H.-D.; Lee, Y.-C.; Ha, K.-S.; Lee, H.; Kwon, H.J.; Kwon, Y.-G.; Kim, Y.-M. Water extract of korean red ginseng stimulates angiogenesis by activating the PI3k/Akt-dependent ERK1/2 and eNOS pathways in human umbilical vein endothelial cells. Biol. Pharm. Bull. 2007, 30, 1674-1679
299. Maiti, K.; Mukherjee, K.; Gantait, A.; Saha, B.P.; Mukherjee, P.K. Curcumin-phospholipid complex: Preparation, therapeutic evaluation and pharmacokinetic study in rats. Int. J. Pharm. 2007, 330, 155-163
300. Muriel, P. NF-κB in liver diseases: A target for drug therapy. J. Appl. Toxicol. 2009, 29, 91-100
301. Zhang, X.-P.; Zhang, F.; Zhang, Z.-L.; Ma, J.; Kong, D.-S.; Ni, G.-X.; Wang, A.-Y.; Chen, W.-X.; Lu, Y.; Zheng, S.-Z. Acupuncture combined with curcumin disrupts platelet-derived growth factor β receptor/extracellular signal-regulated kinase signalling and stimulates extracellular matrix degradation in carbon tetrachloride-induced hepatic fibrosis in rats. Acupunct. Med. 2012, 30, 324-330
302. Yao, Q.-Y.; Xu, B.-L.; Wang, J.-Y.; Liu, H.-C.; Zhang, S.-C.; Tu, C.-T. Inhibition by curcumin of multiple sites of the transforming growth factor-β1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC Complement. Altern. Med. 2012, 12
303. Shu, J.-C.; He, Y.-J.; Lv, X.; Ye, G.-R.; Wang, L.-X. Curcumin prevents liver fibrosis by inducing apoptosis and suppressing activation of hepatic stellate cells. J. Nat. Med. 2009, 63, 415-420
304. Morsy, M.; Abdalla, A.; Mahmoud, A.; Abdelwahab, S.; Mahmoud, M. Protective effects of curcumin, α-lipoic acid, and N-acetylcysteine against carbon tetrachloride-induced liver fibrosis in rats. J. Physiol. Biochem. 2012, 68, 29-35
305. Fu, Y.; Zheng, S.; Lin, J.; Ryerse, J.; Chen, A. Curcumin protects the rat liver from CCL4-caused injury and fibrogenesis by attenuating oxidative stress and suppressing inflammation. Mol. Pharmacol. 2008, 73, 399-409
306. Priya, S.; Sudhakaran, P.R. Curcumin-induced recovery from hepatic injury involves induction of apoptosis of activated hepatic stellate cells. Indian J. Biochem. Biophys. 2008, 45, 317-325
307. Hassan, Z.K.; Al-Olayan, E.M. Curcumin reorganizes mirna expression in a mouse model of liver fibrosis. Asian Pac. J. Cancer Prev. 2012, 13, 5405-5408
308. Wu, S.-J.; Tam, K.-W.; Tsai, Y.-H.; Chang, C.-C.; Chao, J.C.-J. Curcumin and saikosaponin a inhibit chemical-induced liver inflammation and fibrosis in rats. Am. J. Chin. Med. 2010, 38, 99-111
309. Bassiouny, A.R.; Zaky, A.; Kandeel, K.M. Alteration of AP-endonuclease1 expression in curcumin-treated fibrotic rats. Ann. Hepatol. 2011, 10, 516-530
310. Tang, Y.; Zheng, S.; Chen, A. Curcumin eliminates leptin’s effects on hepatic stellate cell activation via interrupting leptin signaling. Endocrinology 2009, 150, 3011-3020
311. Youcai, T.; Anping, C. Curcumin eliminates the effect of advanced glycation end-products (ages) on the divergent regulation of gene expression of receptors of ages by interrupting leptin signaling. Lab. Investig. 2014, 94, 503-516.
312. Lee, Y.K.; Park, S.Y.; Kim, Y.M.; Park, O.J. Regulatory effect of the AMPK-COX-2 signaling pathway in curcumin-induced apoptosis in HT-29 colon cancer cells. Ann. N. Y. Acad. Sci. 2009, 11711, 489-494
313. Cayón, A.; Crespo, J.; Mayorga, M.; Guerra, A.; Pons-romero, F. Increased expression of Ob-Rb and its relationship with the overexpression of TGF-β1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis. Liver Int. 2006, 26, 1065-1071
314. Tønnesen, H.H.; Karlsen, J. Studies on curcumin and curcuminoids. Zeitschrift für Lebensmittel-Untersuchung und Forschung 1985, 180, 402-404
315. Chang, R.C.-C.; So, K.-F. Use of anti-aging herbal medicine, Lycium barbarum, against aging-associated diseases. What do we know so far? Cell. Mol. Neurobiol. 2008, 28, 643-652
316. Toyoda-Ono, Y.; Maeda, M.; Nakao, M.; Yoshimura, M.; Sugiura-Tomimori, N.; Fukami, H. 2-O-(β-D-glucopyranosyl)ascorbic acid, a novel ascorbic acid analogue isolated from lycium fruit. J. Agric. Food Chem. 2004, 52, 2092-2096
317. Xia, G.; Xin, N.; Liu, W.; Yao, H.; Hou, Y.; Qi, J. Inhibitory effect of Lycium barbarum polysaccharides on cell apoptosis and senescence is potentially mediated by the p53 signaling pathway. Mol. Med. Rep. 2014, 9, 1237-1241
318. Li, X.M.; Ma, Y.L.; Liu, X.J. Effect of the Lycium barbarum polysaccharides on age-related oxidative stress in aged mice. J. Ethnopharmacol. 2007, 111, 504-511
319. Wu, H.-T.; He, X.-J.; Hong, Y.-K.; Ma, T.; Xu, Y.-P.; Li, H.-H. Chemical characterization of Lycium barbarum polysaccharides and its inhibition against liver oxidative injury of high-fat mice. Int. J. Biol. Macromol. 2010, 46, 540-543
320. Zhang, M.; Chen, H.; Huang, J.; Li, Z.; Zhu, C.; Zhang, S. Effect of Lycium barbarum polysaccharide on human hepatoma QGY7703 cells: Inhibition of proliferation and induction of apoptosis. Life Sci. 2005, 76, 2115-2124
321. Amagase, H.; Sun, B.; Borek, C. Lycium barbarum (GOJI) juice improves in vivo antioxidant biomarkers in serum of healthy adults. Nutr. Res. 2009, 29, 19-25
322. Kong, W.; Wei, J.; Abidi, P.; Lin, M.; Inaba, S.; Li, C.; Wang, Y.; Wang, Z.; Si, S.; Pan, H. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat. Med. 2004, 10, 1344-1351
323. Lee, S.; Lim, H.-J.; Park, J.-H.; Lee, K.-S.; Jang, Y.; Park, H.-Y. Berberine-induced LDLR up-regulation involves JNK pathway. Biochem. Biophys. Res. Commun. 2007, 362, 853-857
324. Hsiang, C.-Y.; Wu, S.-L.; Cheng, S.-E.; Ho, T.-Y. Acetaldehyde-induced interleukin-1β and tumor necrosis factor-α production is inhibited by berberine through nuclear factor-κB signaling pathway in HEPG2 cells. J. Biomed. Sci. 2005, 12, 791-801
325. Yano, H.; Mizoguchi, A.; Fukuda, K.; Haramaki, M.; Ogasawara, S.; Momosaki, S.; Kojiro, M. The herbal medicine sho-saiko-to inhibits proliferation of cancer cell lines by inducing apoptosis and arrest at the g0/g1 phase. Cancer Res. 1994, 54, 448-454
326. Xie, X.; Chang, X.; Chen, L.; Huang, K.; Huang, J.; Wang, S.; Shen, X.; Liu, P.; Huang, H. Berberine ameliorates experimental diabetes-induced renal inflammation and fibronectin by inhibiting the activation of rhoa/rock signaling. Mol. Cell. Endocrinol. 2013, 381, 56-65
327. Bhutada, P.; Mundhada, Y.; Bansod, K.; Tawari, S.; Patil, S.; Dixit, P.; Umathe, S.; Mundhada, D. Protection of cholinergic and antioxidant system contributes to the effect of berberine ameliorating memory dysfunction in rat model of streptozotocin-induced diabetes. Behav. Brain Res. 2011, 220, 30-41
328. Zhou, J.-Y.; Zhou, S.-W. Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor B expression in diabetic rat liver. Fitoterapia 2011, 82, 184-189
329. Lao-Ong, T.; Chatuphonprasert, W.; Nemoto, N.; Jarukamjorn, K. Alteration of hepatic glutathione peroxidase and superoxide dismutase expression in streptozotocin-induced diabetic mice by berberine. Pharm. Biol. 2012, 50, 1007-1012
330. Chatuphonprasert, W.; Lao-Ong, T.; Jarukamjorn, K. Improvement of superoxide dismutase and catalase in streptozotocin-nicotinamide-induced type 2-diabetes in mice by berberine and glibenclamide. Pharm. Biol. 2014, 52, 419-427
331. Wu, D.; Wen, W.; Qi, C.-L.; Zhao, R.-X.; Lü, J.-H.; Zhong, C.-Y.; Chen, Y.-Y. Ameliorative effect of berberine on renal damage in rats with diabetes induced by high-fat diet and streptozotocin. Phytomedicine 2012, 19, 712-718
332. Zhou, J.; Zhou, S.; Tang, J.; Zhang, K.; Guang, L.; Huang, Y.; Xu, Y.; Ying, Y.; Zhang, L.; Li, D. Protective effect of berberine on β cells in streptozotocin- and high-carbohydrate/high-fat diet-induced diabetic rats. Eur. J. Pharmacol. 2009, 606, 262-268
333. Tang, L.-Q.; Wei, W.; Chen, L.-M.; Liu, S. Effects of berberine on diabetes induced by alloxan and a high-fat/high-cholesterol diet in rats. J. Ethnopharmacol. 2006, 108, 109-115
334. Moghaddam, H.; Baluchnejadmojarad, T.; Roghani, M.; Khaksari, M.; Norouzi, P.; Ahooie, M.; Mahboobi, F. Berberine ameliorate oxidative stress and astrogliosis in the hippocampus of STZ-induced diabetic rats. Mol. Neurobiol. 2014, 49, 820-826
335. Del Rio, D.; Stewart, A.J.; Pellegrini, N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr. Metab. Cardiovasc. Dis. 2005, 15, 316-328
336. Ceballos-Picot, I.; Witko-Sarsat, V.; Merad-Boudia, M.; Nguyen, A.T.; Thévenin, M.; Jaudon, M.C.; Zingraff, J.; Verger, C.; Jingers, P.; Descamps-Latscha, B. Glutathione antioxidant system as a marker of oxidative stress in chronic renal failure. Free Radic. Biol. Med. 1996, 21, 845-853
337. Maritim, A.C.; Sanders, R.A.; Watkins, J.B. Diabetes, oxidative stress, and antioxidants: A review. J. Biochem. Mol. Toxicol. 2003, 17, 24-38
338. Bong-Hyuk, C.; In-Sook, A.; Yu-Hee, K.; Ji-Won, P.; So-Young, L.; Chang-Kee, H.; Myoung-Sool, D. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp. Mol. Med. 2006, 38, 599-605.
339. Lou, T.; Zhang, Z.; Xi, Z.; Liu, K.; Li, L.; Liu, B.; Huang, F. Berberine inhibits inflammatory response and ameliorates insulin resistance in hepatocytes. Inflammation 2011, 34, 659-667
340. Jeong, H.W.; Hsu, K.C.; Lee, J.-W.; Ham, M.; Huh, J.Y.; Shin, H.J.; Kim, W.S.; Kim, J.B. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. Am. J. Physiol. Endocrinol. Metab. 2009, 296, E955-E964
341. Wang, Y. Attenuation of berberine on lipopolysaccharide-induced inflammatory and apoptosis responses in β-cells via TLR4-independent JNK/NF-B pathway. Pharm. Biol. 2014, 52, 532-538
342. Shang, W.; Liu, J.; Yu, X.; Zhao, J. [effects of berberine on serum levels of inflammatory factors and inflammatory signaling pathway in obese mice induced by high fat diet]. Zhongguo Zhong Yao Za Zhi = Zhongguo Zhongyao Zazhi = China J. Chin. Mater. Med. 2010, 35, 1474-1477.
343. Junzeng, Z.; Changhao, S.; Alfonso, L.; Yanwen, W.; Yanfeng, C. Berberine improves glucose homeostasis in streptozotocin-induced diabetic rats in association with multiple factors of insulin resistance. ISRN Endocrinol. 2011, 2011
344. Lin, W.-C.; Lin, J.-Y. Five bitter compounds display different anti-inflammatory effects through modulating cytokine secretion using mouse primary splenocytes in vitro. J. Agric. Food Chem. 2011, 59, 184-192
345. Matsumoto, T.; Sakurai, M.H.; Kiyohara, H.; Yamada, H. Orally administered decoction of Kampo (Japanese herbal) medicine,"Juzen-Taiho-To" modulates cytokine secretion and induces NKT cells in mouse liver. Immunopharmacology 2000, 46, 149-161
346. Imazu, Y.; Tsuiji, K.; Toda, T.; Ishige, A.; Sugiyama, K.; Benno, Y.; Watanabe, K.; Kitajima, M. Juzentaihoto reduces post-partial hepatectomy hyperammonemia by stabilizing intestinal microbiota. J. Tradit. Med. 2006, 23, 208-215.
347. Takahashi, Y.; Soejima, Y.; Kumagai, A.; Watanabe, M.; Uozaki, H.; Fukusato, T. Inhibitory effects of japanese herbal medicines Sho-Saiko-To and Juzen-Taiho-To on nonalcoholic steatohepatitis in mice. PLoS ONE 2014, 9, e87279
348. Nakagawa, A.; Yamaguchi, T.; Takao, T.; Amano, H. [Five cases of drug-induced pneumonitis due to Sho-Saiko-To or interferon-α or both]. Nihon Kyobu Shikkan Gakkai Zasshi 1995, 33, 1361-1366
349. Mao, Y.; Zeng, M.; Chen, Y.; Chen, C.; Fu, Q.; Cai, X.; Wu, S.; Chen, Y.; Sun, Y.; Li, J. [Magnesium isoglycyrrhizinate in the treatment of chronic liver diseases: A randomized, double-blind, multi-doses, active drug controlled, multi-center study]. Zhonghua Gan Zang Bing Za Zhi = Zhonghua Ganzangbing Zazhi = Chin. J. Hepatol. 2009, 17, 847-851.
350. Yagura, M.; Murai, S.; Kojima, H.; Tokita, H.; Kamitsukasa, H.; Harada, H. Does the control of alanine aminotransferase levels lead to a regression of liver fibrosis in chronic hepatitis C patients? Hepatol. Res. 2001, 19, 144-157
351. Motoo, Y.; Sawabu, N. Antitumor effects of saikosaponins, baicalin and baicalein on human hepatoma cell lines. Cancer Lett. 1994, 86, 91-95